The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia

The Lancet

Volumn 388, Issue 10050, 2016, Pages 1228-1248

  Altice, Frederick L ^a   Azbel, Lyuba ^b   Stone, Jack ^c   Brooks Pollock, Ellen ^c   Smyrnov, Pavlo ^d   Dvoriak, Sergii ^e   Taxman, Faye S ^f   El Bassel, Nabila ^g   Martin, Natasha K ^c,h   Booth, Robert ⁱ   Stöver, Heino ^j   Dolan, Kate ^k   Vickerman, Peter ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d ALLIANCE FOR PUBLIC HEALTH   (Ukraine)

^e UKRAINIAN INSTITUTE ON PUBLIC HEALTH POLICY   (Ukraine)

^f GEORGE MASON UNIVERSITY   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j FRANKFURT UNIVERSITY OF APPLIED SCIENCES   (Germany)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; TUBERCULOSTATIC AGENT;

ASIA; COMMUNITY; CRIMINAL JUSTICE; DISEASE TRANSMISSION; DRUG DEPENDENCE; EASTERN EUROPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PRISON; PRISONER; PROPHYLAXIS; REVIEW; SECONDARY PREVENTION; SEXUAL BEHAVIOR; TUBERCULOSIS; UKRAINE; CRIME; HIV INFECTIONS; INCIDENCE; OPIATE SUBSTITUTION TREATMENT; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; RISK; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; THERAPY; TRANSMISSION;

ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; ANTIVIRAL AGENTS; ASIA, CENTRAL; CRIME; EUROPE, EASTERN; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; PRISONERS; PRISONS; RISK; RISK FACTORS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULOSIS;

EID: 84992364799     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30856-X     Document Type: Review

References (122)

1. 1 Altice, FL, Kamarulzaman, A, Soriano, VV, Schechter, M, Friedland, GH, Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 376 (2010), 367–387.
2. 2 Singer, M, introduction to syndemics: a systems approach to public and community health, 2009, Jossey-Bass, San Francisco, CA.
3. 3 Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-_en.pdf (accessed May 28, 2016).
4. 4 WHO. Global update on HIV treatment 2013: results, impact and opportunities, 2013, World Health Organization, Geneva.
5. 5 Degenhardt, L, Mathers, BM, Wirtz, AL, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010–2012? A review of the six highest burden countries. Int J Drug Policy 25 (2014), 53–60.
6. 6 Wolfe, D, Carrieri, MP, Shepard, D, Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376 (2010), 355–366.
7. 7 Awofeso, N, Prisons as social determinants of hepatitis C virus and tuberculosis infections. Public Health Rep 125:suppl 4 (2010), 25–33.
8. 8 Latypov, A, Introduction: illicit drugs in Central Asia. Int J Drug Policy, 25, 2014, 1154.
9. 9 Zabransky, T, Mravcik, V, Talu, A, Jasaitis, E, Post-Soviet Central Asia: a summary of the drug situation. Int J Drug Policy 25 (2014), 1186–1194.
10. 10 Jolley, E, Rhodes, T, Platt, L, et al. HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open, 2, 2012, e001465.
11. 11 Walmsley, R, World prison population list, 10th edn., 2014, University of Essex, London.
12. 12 Stuckler, D, Basu, S, McKee, M, King, L, Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc Natl Acad Sci USA 105 (2008), 13280–13285.
13. 13 Stuckler, D, King, LP, Basu, S, International Monetary Fund programs and tuberculosis outcomes in post-communist countries. PLoS Med, 5, 2008, e143.
14. 14 Basu, S, Stuckler, D, McKee, M, Addressing institutional amplifiers in the dynamics and control of tuberculosis epidemics. Am J Trop Med Hyg 84 (2011), 30–37.
15. 15 Rhodes, T, The ‘risk environment’: a framework for understanding and reducing drug-related harm. Int J Drug Policy 13 (2002), 85–94.
16. 16 Rhodes, T, Singer, M, Bourgois, P, Friedman, SR, Strathdee, SA, The social structural production of HIV risk among injecting drug users. Soc Sci Med 61 (2005), 1026–1044.
17. 17 Izenberg, JM, Bachireddy, C, Wickersham, JA, et al. Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence and correlates of an extremely high-risk behaviour. Int J Drug Policy 25 (2014), 845–852.
18. 18 Dolan, K, Moazen, B, Noori, A, Rahimzadeh, S, Farzadfar, F, Hariga, F, People who inject drugs in prison: HIV prevalence, transmission and prevention. Int J Drug Policy 26:suppl 1 (2015), S12–S15.
19. 19 Culbert, GJ, Waluyo, A, Iriyanti, M, Muchransyah, AP, Kamarulzaman, A, Altice, FL, Within-prison drug injection among HIV-infected male prisoners in Indonesia: a highly constrained choice. Drug Alcohol Depend 149 (2015), 71–79.
20. 20 Culbert, GJ, Earnshaw, VA, Wulanyani, NMS, Wegman, MP, Waluyo, A, Altice, FL, Correlates and experiences of HIV stigma in prisoners living with HIV in Indonesia: a mixed-method analysis. J Assoc Nurses AIDS Care 26 (2015), 743–757.
21. 21 Rhodes, T, The ‘risk environment’: a framework for understanding and reducing drug-related harm. Int J Drug Policy 13 (2002), 85–94.
22. 22 Toni, T, Welch, D, Strelkowa, N, Ipsen, A, Stumpf, MP, Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems. J R Soc Interface 6 (2009), 187–202.
23. 23 Azbel, L, Wickersham, JA, Grishaev, Y, Dvoryak, S, Altice, FL, Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS One, 8, 2013, e59643.
24. 24 Azbel, L, Wickersham, JA, Grishaev, Y, Dvoryak, S, Altice, FL, Correlates of HIV infection and being unaware of HIV status among soon-to-be-released Ukrainian prisoners. J Int AIDS Soc, 17, 2014, 19005.
25. 25 Makarenko, J, Mazhnaya, A, Polonsky, M, et al. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug Alcohol Depend, 2016, 10.1016/j.drugalcdep.2016.06.011 published online June 17.
26. 26 International HIV/AIDS Alliance of Ukraine. Integrated behavioral and biological assessment 2013—national survey of PWID (n=9502) in 29 cities 2013. http://www.aidsalliance.org.ua/ru/library/our/2014/arep14/zvit%20IDU_obl_eng.pdf (accessed Sept 14, 2015).
27. 27 Wickersham, JA, Zahari, MM, Azar, MM, Kamarulzaman, A, Altice, FL, Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend 132 (2013), 378–382.
28. 28 Kinlock, TW, Gordon, MS, Schwartz, RP, Fitzgerald, TT, O'Grady, KE, A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat 37 (2009), 277–285.
29. 29 Dolan, KA, Shearer, J, MacDonald, M, Mattick, RP, Hall, W, Wodak, AD, A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 72 (2003), 59–65.
30. 30 Rich, JD, McKenzie, M, Larney, S, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet 386 (2015), 350–359.
31. 31 Sprinson, JE, Lawton, ES, Porco, TC, Flood, JM, Westenhouse, JL, Assessing the validity of tuberculosis surveillance data in California. BMC Public Health, 6, 2006, 217.
32. 32 The World Bank. Incidence of tuberculosis (per 100,000 people). http://data.worldbank.org/indicator/SH.TBS.INCD, 2015 (accessed Sept 12, 2015).
33. 33 Baussano, I, Williams, BG, Nunn, P, Beggiato, M, Fedeli, U, Scano, F, Tuberculosis incidence in prisons: a systematic review. PLoS Med, 7, 2010, e1000381.
34. 34 Getahun, H, Gunneberg, C, Sculier, D, Verster, A, Raviglione, M, Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS 7 (2012), 345–353.
35. 35 Sacchi, FP, Praca, RM, Tatara, MB, et al. Prisons as reservoir for community transmission of tuberculosis, Brazil. Emerg Infect Dis 21 (2015), 452–455.
36. 36 WHO. Azerbaijan brings quality tuberculosis care to prisons. http://www.who.int/features/2015/azerbaijan-tb/en/, 2015 (accessed Sept 9, 2015).
37. 37 UNODC, WHO Health Organization Regional Office for Europe. Good governance for prison health in the 21st century. A policy brief on the organization of prison health, 2013, United Nations Office on Drugs and Crime and World Health Organization Regional Office for Europe, Copenhagen.
38. 38 Elovich, R, Drucker, E, On drug treatment and social control: Russian narcology's great leap backwards. Harm Reduct J, 5, 2008, 23.
39. 39 Rhodes, T, Sarang, A, Vickerman, P, Hickman, M, Policy resistance to harm reduction for drug users and potential effect of change. BMJ, 341, 2010, c3439.
40. 40 Polonsky, M, Azbel, L, Wickersham, JA, et al. Challenges to implementing opioid substitution therapy in Ukrainian prisons: personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Drug Alcohol Depend 148 (2015), 47–55.
41. 41 MacArthur, GJ, Minozzi, S, Martin, N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ, 345, 2012, e5945.
42. 42 Kim, SW, Pulkki-Brannstrom, AM, Skordis-Worrall, J, Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine. Cost Eff Res Alloc, 12, 2014, 25.
43. 43 Alistar, SS, Owens, DK, Brandeau, ML, Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med, 8, 2011, e1000423.
44. 44 United Nations Office on Drugs and Crime (UNODC). Policy Brief: HIV prevention, treatment and care in prisons and other closed settings: a comprehensive package of interventions. Vienna, Austria. http://www.unodc.org/documents/hiv-aids/HIV_comprehensive_package_prison__eBook.pdf, 2013 (Sept 29, 2013).
45. 45 Sarang, A, Stuikyte, R, Bykov, R, Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy 18 (2007), 129–135.
46. 46 Torrens, M, Fonseca, F, Castillo, C, Domingo-Salvany, A, Methadone maintenance treatment in Spain: the success of a harm reduction approach. Bull World Health Organ 91 (2013), 136–141.
47. 47 Polonsky, M, Azbel, L, Wickersham, JA, et al. Accessing methadone within Moldovan prisons: prejudice and myths amplified by peers. Int J Drug Policy 29 (2016), 91–95.
48. 48 Polonsky, M, Rozanova, J, Azbel, L, et al. Attitudes toward addiction, methadone treatment, and recovery among HIV-infected Ukrainian prisoners who inject drugs: incarceration effects and exploration of mediators. AIDS Behav, 2016 published online March 24.
49. 49 Schluger, NW, El-Bassel, N, Hermosilla, S, et al. Tuberculosis, drug use and HIV infection in Central Asia: an urgent need for attention. Drug Alcohol Depend 132:suppl 1 (2013), S32–S36.
50. 50 Walsh, N, Maher, L, HIV and HCV among people who inject drugs in Central Asia. Drug Alcohol Depend 132:suppl 1 (2013), S37–S40.
51. 51 Kazatchkine, M, Drug use, HIV, HCV and TB: major interlinked challenges in Eastern Europe and Central Asia. J Int AIDS Soc, 17(4 suppl 3), 2014, 19501.
52. 52 Pokrovskiy, V, HIV epidemic in Russia and neighbouring countries. J Int AIDS Soc, 17(4 suppl 3), 2014, 19502.
53. 53 Pridemore, W, Criminological Transition? Change and stability in homicide characteristics during rapid social change. Br J Criminol 47 (2007), 331–345.
54. 54 World Health Organization (WHO). HIV in Prisons. http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/policy/policy-guidance-for-key-populations-most-at-risk2/hiv-in-prisons, 2015 (accessed Aug 7, 2015).
55. 55 Larney, S, Kopinski, H, Beckwith, CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 58 (2013), 1215–1224.
56. 56 Latypov, A, Grund, JP, El-Bassel, N, Platt, L, Stover, H, Strathdee, S, Illicit drugs in Central Asia: what we know, what we don't know, and what we need to know. Int J Drug Policy 25 (2014), 1155–1162.
57. 57 Izenberg, JM, Bachireddy, C, Soule, M, Kiriazova, T, Dvoryak, S, Altice, FL, High rates of police detention among recently released HIV-infected prisoners in Ukraine: Implications for health outcomes. Drug Alcohol Depend 133 (2013), 154–160.
58. 58 Mimiaga, MJ, Safren, SA, Dvoryak, S, Reisner, SL, Needle, R, Woody, G, “We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care 22 (2010), 1305–1313.
59. 59 Azbel, L, Wickersham, JA, Wegman, MP, et al. Burden of substance use disorders, mental illness, and correlates of infectious diseases among soon-to-be released prisoners in Azerbaijan. Drug Alcohol Depend 151 (2015), 68–75.
60. 60 Azbel L, Polonsky M, Wegman M, et al. Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan. Int J Drug Policy (in press).
61. 61 Vagenas, P, Azbel, L, Polonsky, M, et al. A review of medical and substance use co-morbidities in Central Asian prisons: implications for HIV prevention and treatment. Drug Alcohol Depend 132:suppl 1 (2013), S25–S31.
62. 62 Thoreson, R, From child protection to children's rights: rethinking homosexual propaganda bans in human rights law. Yale Law J 124 (2015), 1327–1344.
63. 63 UNAIDS. Global Report: UNAIDS report on the global AIDS epidemic 2013, 2013, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva.
64. 64 Stöver, H, Teltzrow, R, Treatment systems in prisons in Eastern and Southeastern Europe, 2016, Council of Europe/Pompidou Group, Strasbourg.
65. 65 Jurgens, R, Ball, A, Verster, A, Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 9 (2009), 57–66.
66. 66 Kinner, SA, Jenkinson, R, Gouillou, M, Milloy, MJ, High-risk drug-use practices among a large sample of Australian prisoners. Drug Alcohol Depend 126 (2012), 156–160.
67. 67 Caplinskiene, I, Caplinskas, S, Griskevicius, A, Narcotic abuse and HIV infection in prisons. Medicina (Kaunas) 39 (2003), 797–803 (in Lithuanian).
68. 68 Lucas, GM, Solomon, SS, Srikrishnan, AK, et al. High HIV burden among people who inject drugs in 15 Indian cities. AIDS 29 (2015), 619–628.
69. 69 Milloy, MJ, Montaner, JS, Wood, E, Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep 11 (2014), 308–316.
70. 70 McNairy, ML, Deryabina, A, Hoos, D, El-Sadr, WM, Antiretroviral therapy for prevention of HIV transmission: potential role for people who inject drugs in Central Asia. Drug Alcohol Depend 132:suppl 1 (2013), S65–S70.
71. 71 Joint United Nations Programme on HIV/AIDS. 90-90-90—an ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/en/resources/documents/4/90-90-90 (accessed March 12, 2015).
72. 72 DeHovitz, J, Uuskula, A, El-Bassel, N, The HIV epidemic in Eastern Europe and Central Asia. Curr HIV/AIDS Rep 11 (2014), 168–176.
73. 73 Iroh, PA, Mayo, H, Nijhawan, AE, The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health 105 (2015), e5–16.
74. 74 Meyer, JP, Zelenev, A, Wickersham, JA, Williams, CT, Teixeira, PA, Altice, FL, Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study. Am J Public Health 104 (2014), 434–441.
75. 75 Meyer, JP, Cepeda, J, Taxman, FS, Altice, FL, Sex-related disparities in criminal justice and HIV treatment outcomes: a retrospective cohort study of HIV-infected inmates. Am J Public Health 105 (2015), 1901–1910.
76. 76 Zampino, R, Coppola, N, Sagnelli, C, Di Caprio, G, Sagnelli, E, Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol 7 (2015), 2323–2330.
77. 77 Lin, W, Weinberg, EM, Chung, RT, Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis 207:suppl 1 (2013), S13–S18.
78. 78 Bednasz, CJ, Sawyer, JR, Martinez, A, et al. Recent advances in management of the HIV/HCV coinfected patient. Future Virol 10 (2015), 981–997.
79. 79 Mitruka, K, Tsertsvadze, T, Butsashvili, M, et al. Launch of a nationwide hepatitis C elimination program. MMWR Morb Mort Wkly Rep 64 (2015), 753–757.
80. 80 Gelmanova, IY, Ahmad Khan, F, Becerra, MC, et al. Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia. Int J Tuberc Lung Dis 19 (2015), 399–405.
81. 81 Gelmanova, IY, Keshavjee, S, Golubchikova, VT, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 85 (2007), 703–711.
82. 82 Müller-Nordhorn, J, Holmberg, C, Dokova, KG, et al. Perceived challenges to public health in Central and Eastern Europe: a qualitative analysis. BMC Public Health, 12, 2012, 311.
83. 83 Acosta, CD, Dadu, A, Ramsay, A, Dara, M, Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward. Public Health Action 4:suppl 2 (2014), S3–12.
84. 84 Lange, C, Abubakar, I, Alffenaar, JWC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44 (2014), 23–63.
85. 85 Efsen, AMW, Schultze, A, Post, FA, et al. Major challenges in clinical management of TB/HIV coinfected patients in Eastern Europe Compared with Western Europe and Latin America. PLoS One, 10, 2015, e0145380.
86. 86 Migliori, GB, Dara, M, de Colombani, P, Kluge, H, Raviglione, MC, Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?. Eur Respir J 39 (2012), 1290–1291.
87. 87 Skrahina, A, Hurevich, H, Zalutskaya, A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 39 (2012), 1425–1431.
88. 88 WHO. Global Tuberculosis Report 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf (accessed Dec 13, 2013).
89. 89 WHO. Prisons and Health, 2014, Regional Office of Europe, Copenhagen.
90. 90 Dara, M, Chadha, SS, Vinkeles Melchers, NV, et al. Time to act to prevent and control tuberculosis among inmates. Int J Tuberc Lung Dis 17 (2013), 4–5.
91. 91 Abubakar, I, Dara, M, Manissero, D, Zumla, A, Tackling the spread of drug-resistant tuberculosis in Europe. Lancet 379 (2012), e21–e23.
92. 92 El-Bassel, N, Shaw, SA, Dasgupta, A, Strathdee, SA, Drug use as a driver of HIV risks: re-emerging and emerging issues. Curr Opin HIV AIDS 9 (2014), 150–155.
93. 93 Arinaminpathy, N, Dye, C, Health in financial crises: economic recession and tuberculosis in Central and Eastern Europe. J R Soc Interface 7 (2010), 1559–1569.
94. 94 Skrahina, A, Hurevich, H, Zalutskaya, A, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 91 (2013), 36–45.
95. 95 Ministry of Health of the Russian Federation. Tuberculosis in the Russian Federation, 2009. An analytical review of the TB statistical indicators used in the Russian Federation, 2009, Ministry of Health of the Russian Federation, Moscow http://www.mednet.ru/images/stories/files/static/VOZ_tub_09_eng.pdf (accessed Sept 16, 2015).
96. 96 WHO. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015, 2015, World Health Organization, Geneva http://whqlibdoc.who.int/publications/1/9789241501330_eng.pdf (accessed Sept 9, 2015).
97. 97 Dubrovina, I, Miskinis, K, Lyepshina, S, et al. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics?. Int J Tuberc Lung Dis 12 (2008), 756–762.
98. 98 Dara, M, Grzemska, M, Kimerling, ME, Reyes, H, Zagorskiy, X, Guidelines for control of tuberculosis in prisons, 2009, Tuberculosis Coalition for Technical Assistance and International Committee of the Red Cross, Geneva.
99. 99 International HIV/AIDS Alliance in Ukraine. Integrated behavioral and biological assessment 2015—national survey of PWID, 2015, International HIV/AIDS Alliance in Ukraine, Kiev.
100. 100 International HIV/AIDS Alliance of Ukraine. Integrated behavioral and biological assessment 2011—national survey of PWID (n=9069) in 26 cities 2011. http://www.aidsalliance.org.ua/ru/library/our/2012/me/idu_en_2011.pdf (accessed Sept 14, 2015).
101. 101 Grau, LE, White, E, Niccolai, LM, et al. HIV disclosure, condom use, and awareness of HIV infection among HIV-positive, heterosexual drug injectors in St. Petersburg, Russian Federation. AIDS Behav 15 (2011), 45–57.
102. 102 Li, L, Assanangkornchai, S, Duo, L, McNeil, E, Li, J, Risk behaviors, prevalence of HIV and hepatitis C virus infection and population size of current injection drug users in a China-Myanmar border city: results from a Respondent-Driven Sampling Survey in 2012. PLoS One, 9, 2014, e106899.
103. 103 Allen, EJ, Palmateer, NE, Hutchinson, SJ, Cameron, S, Goldberg, DJ, Taylor, A, Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int J Drug Policy 23 (2012), 346–352.
104. 104 Cepeda, JA, Niccolai, LM, Lyubimova, A, Kershaw, T, Levina, O, Heimer, R, High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia. Drug Alcohol Depend 147 (2015), 196–202.
105. 105 Milloy, MJS, Buxton, J, Wood, E, Li, K, Montaner, JSG, Kerr, T, Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health, 9, 2009, 156.
106. 106 Booth, RE, Kwiatkowski, CF, Brewster, JT, Sinitsyna, L, Dvoryak, S, Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS 20 (2006), 2217–2223.
107. 107 Maru, DS, Basu, S, Altice, FL, HIV control efforts should directly address incarceration. Lancet Infect Dis 7 (2007), 568–569.
108. 108 Baral, S, Todd, CS, Aumakhan, B, Lloyd, J, Delegchoimbol, A, Sabin, K, HIV among female sex workers in the Central Asian Republics, Afghanistan, and Mongolia: contexts and convergence with drug use. Drug Alcohol Depend 132:suppl 1 (2013), S13–S16.
109. 109 Ancker, S, Rechel, B, Policy responses to HIV/AIDS in Central Asia. Glob Public Health 10 (2015), 817–833.
110. 110 Izenberg, J, Altice, FL, Next steps for Ukraine—abolition of HIV registries, implementation of routine HIV testing and expansion of services. Addiction 105 (2010), 569–570.
111. 111 Bojko, MJ, Mazhnaya, A, Makarenko, I, et al. “Bureaucracy & beliefs”: assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine. Drugs (Abingdon Engl) 22 (2015), 255–262.
112. 112 Scutelniciuc, O, Bivol, S, Plamadeala, D, Slobozian, V, Behavioral surveillance survey among IDUs who are beneficiaries of harm reduction programs. In: Moldova Ministry of Health, ed. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). http://www.emcdda.europa.eu/publications/country-overviews/md, 2009 (accessed Sept 7, 2015).
113. 113 Mazhnaya, A, Bojko, MJ, Makarenko, I, et al. In their own voices: breaking the vicious cycle of addiction, treatment and criminal justice among people who inject drugs in Ukraine. Drugs Educ Prev Policy 23 (2016), 163–175.
114. 114 Spicer, N, Harmer, A, Aleshkina, J, et al. Circus monkeys or change agents? Civil society advocacy for HIV/AIDS in adverse policy environments. Soc Sci Med 73 (2011), 1748–1755.
115. 115 Booth, RE, Dvoryak, S, Sung-Joon, M, et al. Law enforcement practices associated with HIV infection among injection drug users in Odessa, Ukraine. AIDS Behav 17 (2013), 2604–2614.
116. 116 Lunze, K, Raj, A, Cheng, DM, et al. Punitive policing and associated substance use risks among HIV-positive people in Russia who inject drugs. J Int AIDS Soc, 17, 2014, 19043.
117. 117 Kivimets, K, Uuskula, A, HIV testing and counselling in Estonian prisons, 2012 to 2013: aims, processes and impacts. Euro Surveill, 19, 2014, 20970.
118. 118 Cakalo, JI, Bozicevic, I, Vitek, C, Mandel, JS, Salyuk, T, Rutherford, GW, Misclassification of men with reported HIV infection in Ukraine. AIDS Behav 19 (2015), 1938–1940.
119. 119 Bojko, MJ, Dvoriak, S, Altice, FL, At the crossroads: HIV prevention and treatment for people who inject drugs in Ukraine. Addiction 108 (2013), 1697–1699.
120. 120 United Nations. 45/111. Basic principles for the treatment of prisoners. http://www.un.org/documents/ga/res/45/a45r111.htm, 1990 (accessed March 12, 2010).
121. 121 Bretschneider, W, Elger, BS, Expert perspectives on Western European prison health services: do ageing prisoners receive equivalent care?. J Bioeth Inq 11 (2014), 319–332.
122. 122 Office of the High Commissioner for Human Rights. CESCR General Comment No. 14: the Right to the Highest Attainable Standard of Health (Art. 12). http://www.refworld.org/pdfid/4538838d0.pdf (accessed July 29, 2009).